Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors.

PubWeight™: 1.46‹?› | Rank: Top 5%

🔗 View Article (PMID 10211965)

Published in J Gen Virol on April 01, 1999

Authors

A Alcamí1, A Khanna, N L Paul, G L Smith

Author Affiliations

1: Sir William Dunn School of Pathology, University of Oxford, UK.

Articles citing this

Chemical control of protein stability and function in living mice. Nat Med (2008) 2.37

The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol (2000) 2.08

Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68

A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci U S A (2006) 1.57

Poxvirus immunomodulatory strategies: current perspectives. J Virol (2003) 1.52

Genome of horsepox virus. J Virol (2006) 1.42

Chasing Jenner's vaccine: revisiting cowpox virus classification. PLoS One (2011) 1.33

Human cytomegalovirus infection inhibits tumor necrosis factor alpha (TNF-alpha) signaling by targeting the 55-kilodalton TNF-alpha receptor. J Virol (2003) 1.28

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One (2008) 1.23

Expression of secreted cytokine and chemokine inhibitors by ectromelia virus. J Virol (2000) 1.20

The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics (2009) 1.20

Inhibition of interferons by ectromelia virus. J Virol (2002) 1.15

Genome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipients. Hum Genet (2012) 1.15

Comparative proteomics of human monkeypox and vaccinia intracellular mature and extracellular enveloped virions. J Proteome Res (2008) 1.13

Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J Virol (2006) 1.12

CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses. J Virol (2001) 1.07

Monkeypox virus and insights into its immunomodulatory proteins. Immunol Rev (2008) 1.07

Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J Exp Med (2002) 1.05

The vaccinia virus superoxide dismutase-like protein (A45R) is a virion component that is nonessential for virus replication. J Virol (2001) 1.00

Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J Virol (2003) 1.00

Mapping the IkappaB kinase beta (IKKbeta)-binding interface of the B14 protein, a vaccinia virus inhibitor of IKKbeta-mediated activation of nuclear factor kappaB. J Biol Chem (2011) 0.97

An ectromelia virus protein that interacts with chemokines through their glycosaminoglycan binding domain. J Virol (2007) 0.96

Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. J Virol (2006) 0.89

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol (2012) 0.87

A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants. PLoS One (2009) 0.87

Blockade of virus infection by human CD4+ T cells via a cytokine relay network. J Immunol (2008) 0.87

Vaccinia virus inhibits NF-κB-dependent gene expression downstream of p65 translocation. J Virol (2013) 0.85

Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine. J Infect Dis (2010) 0.82

Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice. J Virol (2011) 0.81

Early viral protein synthesis is necessary for NF-kappaB activation in modified vaccinia Ankara (MVA)-infected 293 T fibroblast cells. Virology (2009) 0.80

New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens. Virology (2009) 0.80

Genetic variability of immunomodulatory genes in ectromelia virus isolates detected by denaturing high-performance liquid chromatography. J Virol (2003) 0.78

Analysis of the anti-apoptotic activity of four vaccinia virus proteins demonstrates that B13 is the most potent inhibitor in isolation and during viral infection. J Gen Virol (2014) 0.77

Comparative Biochemical and Functional Analysis of Viral and Human Secreted Tumor Necrosis Factor (TNF) Decoy Receptors. J Biol Chem (2015) 0.77

Articles by these authors

General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98

Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A (1982) 7.81

Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1985) 5.42

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature (1983) 5.25

Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med (1998) 4.13

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene (1983) 3.94

A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A (2000) 3.69

Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature (1985) 3.62

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell (1995) 3.51

A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell (1992) 3.36

Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature (1984) 3.21

Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature (1984) 3.03

Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol (1999) 2.95

Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus. Virology (1994) 2.89

The effects of metabolic inhibition on intracellular calcium and pH in isolated rat ventricular cells. J Physiol (1989) 2.86

Vaccinia virus expression vectors. J Gen Virol (1986) 2.84

Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med (1988) 2.73

A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology (1992) 2.67

The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology (1993) 2.66

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol (1998) 2.55

IPTG-dependent vaccinia virus: identification of a virus protein enabling virion envelopment by Golgi membrane and egress. Nucleic Acids Res (1990) 2.41

Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress. J Virol (1992) 2.35

Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H. J Virol (1988) 2.34

Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science (1987) 2.24

Vaccinia virus intracellular mature virions contain only one lipid membrane. J Virol (1999) 2.24

Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol (1986) 2.16

Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol (1998) 2.14

Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol (2001) 2.10

The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol (2000) 2.08

Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol (1995) 2.07

Vaccinia virus immune evasion. Immunol Rev (1997) 2.03

EGTA purity and the buffering of calcium ions in physiological solutions. Am J Physiol (1984) 2.03

Transient inhibition of polyoma virus synthesis by Sendai virus (parainfluenza I). I. Demonstration and nature of the inhibition by inactivated virus. J Virol (1972) 2.01

Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J Virol (1996) 2.01

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A (1998) 1.97

Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol (1998) 1.94

Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg (2000) 1.89

Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J Virol (1987) 1.88

A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors. J Virol (1997) 1.86

Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion. J Gen Virol (1998) 1.81

K201 modulates excitation-contraction coupling and spontaneous Ca2+ release in normal adult rabbit ventricular cardiomyocytes. Cardiovasc Res (2007) 1.76

Inducible gene expression from vaccinia virus vectors. Virology (1990) 1.76

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine (1998) 1.74

Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus. J Virol (1986) 1.73

Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer. Lancet (1999) 1.70

Interactions between vaccinia virus IEV membrane proteins and their roles in IEV assembly and actin tail formation. J Virol (1999) 1.68

Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. Immunol Today (1995) 1.68

Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int (1998) 1.66

Comparative risks and costs of male and female sterilization. Am J Public Health (1985) 1.65

Potentiometric measurements of stoichiometric and apparent affinity constants of EGTA for protons and divalent ions including calcium. Biochim Biophys Acta (1985) 1.65

Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol (1986) 1.62

Current attitudes to burns resuscitation in the UK. Burns (2001) 1.57

Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J Clin Pathol (1990) 1.57

Calcium-induced calcium release activates contraction in intact cardiac cells. Pflugers Arch (1989) 1.57

The vaccinia virus A36R protein is a type Ib membrane protein present on intracellular but not extracellular enveloped virus particles. Virology (2000) 1.56

Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J Gen Virol (1997) 1.54

The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. J Gen Virol (2000) 1.52

Vaccinia virus gene B1R encodes a 34-kDa serine/threonine protein kinase that localizes in cytoplasmic factories and is packaged into virions. Virology (1992) 1.50

Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol (1997) 1.49

The genome sequence of Yaba-like disease virus, a yatapoxvirus. Virology (2001) 1.48

The influence of tackle parameters on the propensity for injury in international football. Am J Sports Med (2004) 1.47

Integral role of interventional radiology in the development of a pediatric liver transplantation program. Pediatr Transplant (2001) 1.47

Lack of HIV infection and condom use in licensed prostitutes. Lancet (1986) 1.46

Preliminary studies of absorption and excretion of benoxaprofen in man. Br J Clin Pharmacol (1977) 1.46

Replication of the influenza virus genome. Virology (1982) 1.45

Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus. Science (1984) 1.42

S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci U S A (2001) 1.42

Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med (1991) 1.40

Vascular access for hemodialysis: an indepth review. J Nephrol (2001) 1.40

Testicular prosthesis placement: a new technique. BJU Int (1999) 1.40

A new clinical test in gastroduodenal perforation. J Indian Med Assoc (1991) 1.39

A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci U S A (1996) 1.39

Field evaluation of Haemophilus somnus bacterin. Vet Med Small Anim Clin (1977) 1.38

Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence. J Virol (2000) 1.38

Circumcision as a risk factor for urethritis in racial groups. Am J Public Health (1987) 1.38

The relationship between intracellular calcium and contraction in calcium-overloaded ferret papillary muscles. J Physiol (1985) 1.37

Purified multiplication-stimulating activity from rat liver cell conditioned medium: comparison of biological activities with calf serum, insulin, and somatomedin. J Cell Physiol (1974) 1.37

Difficulties encountered in the search for the etiologic agents of destructive periodontal diseases. J Clin Periodontol (1987) 1.35

Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology (1995) 1.34

A systematic review of enhanced recovery protocols in colorectal surgery. Ann R Coll Surg Engl (2011) 1.34

The PA influenza virus polymerase subunit is a phosphorylated protein. J Gen Virol (1998) 1.33

Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology (2001) 1.32

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J Gen Virol (1998) 1.32

Simultaneous measurements of action potential duration and intracellular ATP in isolated ferret hearts exposed to cyanide. Circ Res (1989) 1.31

Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity. Mol Cell Biol (1986) 1.31

An evaluation of direct access radiology in general practice. J R Coll Gen Pract (1979) 1.31

Metabolic consequences of increasing intracellular calcium and force production in perfused ferret hearts. J Physiol (1986) 1.30

In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation (1998) 1.29

A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol (1999) 1.29

Immunogenicity of a Haemophilus somnus bacterin in cattle. Am J Vet Res (1978) 1.27

The electrophysiological and mechanical effects of 2,3-butane-dione monoxime and cytochalasin-D in the Langendorff perfused rabbit heart. Exp Physiol (2004) 1.25

Rural vs urban motor vehicle crash death rates: 20 years of FARS data. Prehosp Emerg Care (2000) 1.24

Clinical performance of a rule-based decision support system for mechanical ventilation of ARDS patients. Proc Annu Symp Comput Appl Med Care (1993) 1.23

The extracellular domain of vaccinia virus protein B5R affects plaque phenotype, extracellular enveloped virus release, and intracellular actin tail formation. J Virol (1998) 1.23

Virus-induced cell motility. J Virol (1998) 1.23

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos (2009) 1.22

Fine-needle aspiration biopsy in pancreatic transplantation. Transplant Proc (1995) 1.21